Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

907 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FISH in triple-negative breast cancer: a possible strategy for the future?
Rigon E, Saggia C, Rossi V, Genestroni S, Gaudino E, Campisi P, Veggiani C, Boldorini RL, Alabiso O. Rigon E, et al. Among authors: rossi v. Future Oncol. 2015;11(7):1023-6. doi: 10.2217/fon.15.25. Future Oncol. 2015. PMID: 25804117 Free article. No abstract available.
Breast Cancer Survivorship, Quality of Life, and Late Toxicities.
Nardin S, Mora E, Varughese FM, D'Avanzo F, Vachanaram AR, Rossi V, Saggia C, Rubinelli S, Gennari A. Nardin S, et al. Among authors: rossi v. Front Oncol. 2020 Jun 16;10:864. doi: 10.3389/fonc.2020.00864. eCollection 2020. Front Oncol. 2020. PMID: 32612947 Free PMC article. Review.
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, Dib B, Sacchetti GM, Saggia C, Rossi V, Harbeck N, Wuerstlein R, Degenhardt T, DeCensi A, Rollandi GA, Gennari A. Bottoni G, et al. Among authors: rossi v. Eur J Radiol. 2021 Aug;141:109821. doi: 10.1016/j.ejrad.2021.109821. Epub 2021 Jun 10. Eur J Radiol. 2021. PMID: 34139575 Free article.
2013 San Antonio Breast Cancer Symposium.
Rossi V, Martinello R, Aversa C, Montemurro F. Rossi V, et al. Expert Opin Pharmacother. 2014 Jun;15(8):1191-5. doi: 10.1517/14656566.2014.904288. Epub 2014 Apr 3. Expert Opin Pharmacother. 2014. PMID: 24697336
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P, Sapino A, Aglietta M, Baselga J, Scaltriti M. Montemurro F, et al. Among authors: rossi v. Mol Oncol. 2014 Feb;8(1):20-6. doi: 10.1016/j.molonc.2013.08.013. Epub 2013 Sep 13. Mol Oncol. 2014. PMID: 24075779 Free PMC article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Underuse of anthracyclines in women with HER-2+ advanced breast cancer.
Montemurro F, Rossi V, Nolè F, Redana S, Donadio M, Martinello R, Verri E, Valabrega G, Rocca MC, Jacomuzzi ME, Viale G, Sapino A, Aglietta M. Montemurro F, et al. Among authors: rossi v. Oncologist. 2010;15(7):665-72. doi: 10.1634/theoncologist.2010-0016. Epub 2010 Jun 24. Oncologist. 2010. PMID: 20576644 Free PMC article.
907 results